Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-3512676 with Pemetrexed in Advanced NSCLC
NCT00321308Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Sep 2006
- Primary completion
- Jan 2008
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of agatolimod in non-small cell lung carcinoma (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival. Started Sep 2006; status: terminated.
02
Drugs
agatolimod
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00321308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321308.